DBDiako Berzenji

Diako Berzenji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Diako Berzenji has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Aniel Sewnaik

    Department of Otorhinolaryngology and Head and Neck Surgery Erasmus MC Cancer Institute Rotterdam The Netherlands

    3 shared publications
  • Hetty Mast

    Department of Oral and Maxillofacial Surgery Erasmus MC Cancer Institute Erasmus University Medical Center Rotterdam the Netherlands

    3 shared publications
  • Jose A. Hardillo

    Department of Otorhinolaryngology and Head and Neck Surgery Erasmus MC Cancer Institute Rotterdam The Netherlands

    3 shared publications
  • Robert J. Baatenburg de Jong

    Department of Otorhinolaryngology and Head and Neck Surgery Erasmus MC Cancer Institute Rotterdam The Netherlands

    3 shared publications
  • Bernd Kremer

    Erasmus MC Department of Otorhinolaryngology Head and Neck Surgery

    2 shared publications
  • Dominiek A. Monserez

    Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands

    2 shared publications

Latest Publications

  • Open Access

    The Septoplasty Healthcare Monitor: An Outcome Assessment Infrastructure to Enhance the Quality and Transparency of Care

    by Victor S. van Dam, Diako Berzenji, Floris V. W. J. van Zijl, Martijn A. H. Oude Voshaar, Bernd Kremer, Frank R. Datema

    Objective and Design: The growing demand for transparency about the efficacy of healthcare has accelerated the use of Patient‐Reported Outcome Measures (PROMs), but their integration into daily practice is challenging. This observational study describes how the Septoplasty Healthcare Monitor (SHM) addresses these challenges and highlights the benefits of standardised outcome assessments and visualisation for various stakeholders, including physicians and patients. Main Outcome Measures: Since 2014, all eligible septoplasty patients have been included in the SHM. Patients are automatically offered the Nasal Obstruction Symptom Evaluation (NOSE) scale and bilateral Visual Analogue Scales (VAS) to assess nasal obstruction before initial consultation and during postoperative visits. Data are entered into a preformatted database and automatically analysed. Real‐time results are visually presented on a user‐friendly dashboard. Results: A total of 173 patients participated. First, the dashboard provides insights into outcomes on a cohort level. The mean NOSE scores significantly decreased from 68.8 ± 19.0 at baseline to 19.8 ± 22.3 at 12 months (Cohen's d = −1.96). VAS scores improved from 4.6 ± 3.0 (left) and 4.7 ± 2.9 (right) preoperatively to 7.5 ± 2.1 (left) and 7.6 ± 1.7 (right) at 12 months ( p < 0.001; d = 0.85; d = 1.05). Second, quality of care is monitored through annual performance metrics and can be improved by critically appraising auto‐identified underperforming patients. Third, visualisation of individual PROM symptom‐severity scores in relation to peers assists in patient‐counselling and shared decision‐making. Conclusion: The integration of standardised outcome assessments into daily practice is highly valuable but challenging. The SHM addresses these challenges and offers opportunities to enhance septoplasty care standards.

  • Open Access

    Validation of the prognostic model “oncologiq palliative” for head and neck cancer patients

    by B. N. van Den Besselaar, D. van Klaveren, D. Berzenji, A. Hoesseini, J. C. Jansen, J. A. Hardillo, R. J. Baatenburg de Jong, M. P. J. Offerman, A. Sewnaik

    Purpose: Patients diagnosed with incurable head and neck squamous cell carcinoma (HNSCC) have a poor prognosis, with a median survival of approximately five months. Physicians often struggle to predict prognosis accurately and tend to overestimate survival. Timely sharing of validated accurate individual information on life expectancy could aid in facilitating better patient counseling. However, this knowledge is lacking. Therefore, the aim of this study is to conduct temporal and external validation of the prognostic model OncologIQ Palliative to assess its accuracy and generalizability. Methods: The validation procedure involved temporal assessment in a retrospective cohort of 355 palliative HNSCC patients from Erasmus MC (2017–2020), followed by external validation in a retrospective cohort of 44 patients from Leiden University Medical Center (2019–2021).The discriminative ability of OncologIQ Palliative was assessed using the C-index and calibration was evaluated through graphical assessment, intercept, and slope. Results: The temporal cohort had a median follow-up of 115 days, and the external cohort 143 days. The model showed moderate discriminative ability in temporal validation (C-index 0.66) and better discrimination in external validation (C-index 0.71). Reasonable agreement was observed between predicted and observed 6-month and 1-year survival rates, with some deviations from the perfect calibration line. Conclusion: The validation methods conducted in this study underscored the reliability of OncologIQ Palliative. They showed adequate calibration and discrimination in both validation procedures, thereby facilitating the provision of more accurate prognostic counselling for head and neck cancer patients in the palliative phase.


  • Open Access

    The Septoplasty Healthcare Monitor: an outcome assessment infrastructure to enhance the quality and transparency of care

    by Victor S. van Dam, Diako Berzenji, Floris van Zijl, Martijn A.H. Oude Voshaar, Bernd Kremer, Frank Datema

    Objective and design: The growing demand for transparency about the efficacy of healthcare has accelerated the use of Patient-Reported Outcome Measures (PROMs), but their integration into daily practice is challenging. This observational study describes how the Septoplasty Healthcare Monitor (SHM) addresses these challenges and highlights the benefits of standardized outcome assessments and visualization for various stakeholders, including physicians and patients. Main outcome measures: Since 2014, all eligible septoplasty patients have been included in the SHM. Patients are automatically offered the Nasal Obstruction Symptom Evaluation (NOSE) scale and bilateral Visual Analogue Scales (VAS) to assess nasal obstruction before initial consultation, and during postoperative visits. Data are entered into a preformatted database and automatically analyzed. Real-time results are visually presented on a user-friendly dashboard. Results: A total of 173 patients participated. First, the dashboard provides insights into outcomes on a cohort level. The mean NOSE scores significantly decreased from 68.8 ± 19.0 at baseline to 19.8 ± 22.3 at 12 months. VAS scores improved from 4.6 ± 3.0 (left) and 4.7 ± 2.9 (right) preoperatively to 7.5 ± 2.1 (left) and 7.6 ± 1.7 (right) at 12 months ( p < 0.001). Second, quality of care is monitored through annual performance metrics, and can be improved by critically appraising auto-identified underperforming patients. Third, visualization of individual PROM symptom-severity scores in relation to peers assists in patient-counseling and shared decision-making. Conclusion: The integration of standardized outcome assessments into daily practice is highly valuable but challenging. The SHM addresses these challenges and offers opportunities to enhance septoplasty care standards.

  • Open Access

    A comprehensive approach to defining the cutoff value of oligometastasis in head and neck squamous cell carcinoma

    by Diako Berzenji, Olivier R. G. Oude Booijink, Renske Gahrmann, Hetty Mast, Marta E. Capala, Sjors A. Koppes, Esther van Meerten, Bernd Kremer, Robert Jan Baatenburg de Jong, Marinella P. J. Offerman, et al.

    Background: Patients with limited distant metastatic disease, also known as oligometastasis, show better survival rates than polymetastatic patients, and may be amenable for curative‐intent treatment. The definition of oligometastasis, however, is unknown, and no quantitative analyses on the cutoff value for oligometastasis have been performed before. This study aims to derive specific threshold values for the number of metastases and affected locations that defines oligometastatic disease in head and neck squamous cell carcinoma.Methods: A retrospective cohort study was conducted including all patients diagnosed with distant metastases between 2006 and 2021. For each patient, the number of distant metastases and affected locations was recorded on the basis of the available imaging at the time of diagnosis. Cox regression analyses and a machine‐learning k‐means algorithm were used to determine threshold values.Results: A total of 384 patients untreated for their metastatic foci were analyzed. Most patients (n = 207; 53.9%) had metastasis to one anatomic location, followed by metastases in two anatomic locations (n = 62; 16.1%). The majority of patients had ≥9 metastatic foci (n = 174; 45.3%), followed by one focus (n = 74; 19.3%) and two foci (n = 32; 8.3%). Cox regression and machine‐learning k‐means models showed that although the number of metastases did not predict survival, the number of affected locations did significantly (p < .001), by identifying a threshold of two locations.Conclusions: Contrary to the prevalent dogma, the definition of oligometastasis should not be defined by the number of metastases but rather by the number of affected locations, with a maximum number of affected locations set at two.


  • Open Access

    Quality of Life of Oligometastatic and Polymetastatic Head and Neck Squamous Cell Carcinoma Patients

    by Diako Berzenji, Maarten C. Dorr, Aniel Sewnaik, Hetty Mast, Marinella P.J. Offerman, Robert J. Baatenburg de Jong, Jose A. Hardillo

    Objective: Evidence suggests that distant metastasis in head and neck squamous cell carcinoma is a spectrum of disease. Previous studies show that oligometastasis has favorable survival compared with polymetastasis. The quality of life of patients with oligometastasis remains unknown. To further solidify the position of oligometastasis as a separate entity, we hypothesized that oligometastatic patients experience better quality of life than polymetastatic patients.Methods: Patients with distant metastasis were stratified into three groups: oligometastasis (≤3 metastatic foci in ≤2 anatomic sites), explosive metastasis (≥4 metastatic foci at one anatomic site), and explosive‐disseminating metastasis (spread to ≥3 anatomic sites). Quality of life was assessed every 2 months post distant metastasis diagnosis.Results: Between January 1, 2016, and December 31, 2021, a total of 161 patients with distant metastasis were identified, with a total of 397 measurements. In this group, 57 (35.4%) patients had oligometastasis, 35 (21.7%) patients had explosive metastasis, and 69 (42.9%) patients had explosive‐disseminating metastasis. Their median post‐distant metastasis survivals were 8.5 months, 3.2 months, and 3.2 months respectively (p < 0.001). A significantly better overall quality of life was observed in the oligometastasis group compared with the polymetastatic groups (+0.75 out of 7, p < 0.05). Furthermore, oligometastatic patients performed better in the subdomains of “physical functioning,” “fatigue,” and “pain.”Conclusion: Results from this study underscore that subgroups exist regarding quality of life and survival within distant metastasis, with polymetastatic patients performing worse than oligometastatic patients. This highlights the significance of tailored interventions that consider the unique challenges faced by each metastatic group of patients.Level of Evidence: 3, retrospective cohort study Laryngoscope, 134:3170–3176, 2024


  • Open Access

    Dissemination patterns and chronology of distant metastasis affect survival of patients with head and neck squamous cell carcinoma

    by Diako Berzenji, Aniel Sewnaik, Stijn Keereweer, Dominiek A. Monserez, Gerda M. Verduijn, Esther van Meerten, Hetty Mast, Marc A.M. Mureau, Aad van der Lugt, Senada Koljenovic, et al.


  • Open Access

    Treatment of head and neck carcinoma of unknown primary: Cracking a nut with a sledgehammer?

    by Diako Berzenji, Dominiek A. Monserez, Gerda M. Verduijn, Emilie A.C. Dronkers, Peter P. Jansen, Stijn Keereweer, Aniel Sewnaik, Robert J. Baatenburg de Jong, Jose A. Hardillo

    Objectives: To compare the impact on survival and late radiation toxicity of patients with squamous cell carcinoma of unknown primary who were treated with ipsilateral neck dissection and ipsilateral postoperative radiotherapy (PORT) and patients treated with ipsilateral neck dissection and PORT to both sides of the neck plus the pharyngeal axis.Methods: Retrospective cohort study performed at the Erasmus University Medical Center in which 78 patients with squamous cell carcinoma of unknown primary were identified. Thirty‐nine patients received PORT to both sides of the neck plus the pharyngeal axis (BILAX) and another 39 patients were irradiated on the ipsilateral neck (IPSI) only. The endpoints of the present study were 3‐year overall survival (OS), 3‐year disease‐free survival (DFS), and overall late radiation toxicity.Results: The 3‐year OS rate of the entire group of 78 patients was 74.2% and the 3‐year DFS rate was 72.7%. The 3‐year OS rates for the IPSI and the BILAX groups were 74.4% and 74.1%, respectively (P = .654). The most common late radiation toxicity experienced was xerostomia (64.8%), which was significantly more often seen in the BILAX group than in the IPSI group (83.8% and 44.1%, respectively, P = .001). Overall late radiation toxicity was significantly higher in the BILAX group (P = .003).Conclusion: There was no significant difference in OS and DFS rates between the IPSI and the BILAX group. Late radiation toxicity was significantly higher in the BILAX group.Level of Evidence: Level 2b: Individual retrospective cohort study.